Opus Genetics (IRD) Competitors $1.13 -0.04 (-3.00%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.15 +0.02 (+2.12%) As of 07/18/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IRD vs. AARD, PRQR, INZY, TRDA, ACB, IMMP, NBTX, FENC, TKNO, and EDITShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Aardvark Therapeutics (AARD), ProQR Therapeutics (PRQR), Inozyme Pharma (INZY), Entrada Therapeutics (TRDA), Aurora Cannabis (ACB), Prima BioMed (IMMP), Nanobiotix (NBTX), Adherex Technologies (FENC), Alpha Teknova (TKNO), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Its Competitors Aardvark Therapeutics ProQR Therapeutics Inozyme Pharma Entrada Therapeutics Aurora Cannabis Prima BioMed Nanobiotix Adherex Technologies Alpha Teknova Editas Medicine Opus Genetics (NASDAQ:IRD) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Which has better earnings and valuation, IRD or AARD? Aardvark Therapeutics has lower revenue, but higher earnings than Opus Genetics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpus Genetics$10.99M6.13-$57.53M-$2.10-0.54Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A Do institutionals and insiders hold more shares of IRD or AARD? 15.0% of Opus Genetics shares are held by institutional investors. 6.6% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor IRD or AARD? In the previous week, Aardvark Therapeutics had 1 more articles in the media than Opus Genetics. MarketBeat recorded 1 mentions for Aardvark Therapeutics and 0 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.00 equaled Aardvark Therapeutics'average media sentiment score. Company Overall Sentiment Opus Genetics Neutral Aardvark Therapeutics Neutral Do analysts recommend IRD or AARD? Opus Genetics currently has a consensus target price of $7.33, suggesting a potential upside of 548.97%. Aardvark Therapeutics has a consensus target price of $33.00, suggesting a potential upside of 183.99%. Given Opus Genetics' higher possible upside, analysts plainly believe Opus Genetics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IRD or AARD more profitable? Aardvark Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -429.42%. Aardvark Therapeutics' return on equity of 0.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Opus Genetics-429.42% -283.28% -144.32% Aardvark Therapeutics N/A N/A N/A SummaryAardvark Therapeutics beats Opus Genetics on 6 of the 10 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.42M$2.93B$5.52B$9.40BDividend YieldN/A2.48%4.00%4.04%P/E Ratio-0.5419.8828.2519.77Price / Sales6.13229.13411.1088.91Price / CashN/A40.8024.9928.17Price / Book5.387.668.095.69Net Income-$57.53M-$55.16M$3.25B$257.97M7 Day Performance1.80%1.10%0.36%1.92%1 Month Performance18.93%13.14%7.70%12.82%1 Year PerformanceN/A3.51%32.74%19.22% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics1.3111 of 5 stars$1.13-3.0%$7.33+549.0%N/A$67.42M$10.99M-0.5414Positive NewsAARDAardvark TherapeuticsN/A$12.11-0.5%$33.00+172.5%N/A$262.74MN/A0.0018PRQRProQR Therapeutics2.1235 of 5 stars$2.48+6.9%$8.00+222.6%+26.6%$260.92M$20.46M-7.09180INZYInozyme Pharma2.8745 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750TRDAEntrada Therapeutics3.2503 of 5 stars$6.80+3.8%$25.67+277.5%-63.1%$258.08M$172.22M8.40110ACBAurora Cannabis0.4089 of 5 stars$4.58+2.0%N/A-21.2%$257.44M$246.72M41.641,130Analyst DowngradeIMMPPrima BioMed0.9768 of 5 stars$1.69+2.4%$7.00+314.2%-12.4%$246.81M$5.14M0.002,021Positive NewsNBTXNanobiotix1.8825 of 5 stars$5.15-0.4%$8.00+55.3%-2.6%$242.72M$39.18M0.00100FENCAdherex Technologies2.2998 of 5 stars$8.79+0.1%$13.00+47.9%+32.1%$242.60M$47.54M-17.2410TKNOAlpha Teknova1.8844 of 5 stars$4.49-6.7%$12.00+167.3%+96.8%$239.95M$38.25M-9.35240EDITEditas Medicine4.1568 of 5 stars$2.85-1.0%$4.70+64.9%-44.8%$238.57M$32.31M-0.94230News Coverage Related Companies and Tools Related Companies Aardvark Therapeutics Alternatives ProQR Therapeutics Alternatives Inozyme Pharma Alternatives Entrada Therapeutics Alternatives Aurora Cannabis Alternatives Prima BioMed Alternatives Nanobiotix Alternatives Adherex Technologies Alternatives Alpha Teknova Alternatives Editas Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRD Stock Alerts